UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Short guide to identifying dividend ETFs with the absolute lowest fees and what to consider beyond price.
27,457 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Britain's PRA has removed licensing limits, allowing Revolut to move ahead with its UK bank launch in a staged rollou...
Howard Hanna launches HannaList, an MLS-aligned early-access portal for selective property launches, starting in Nort...
A large Iranian-linked vessel crossed the Strait of Hormuz, with several others following in a week of heightened sec...
AI hype meets real-world finance. This article explains why I remain cautious on CoreWeave stock, with clear risks, n...
A Fortune 500 firm raises its AI disruption estimate to $4.5 trillion, with 93% of jobs at some risk. The update acce...
Delve into the investing philosophy of Bill Miller IV, the CIO and PM behind Miller Value Fund. Learn how high-convic...
Stocks reversed a sharp rally as fear returned to the market. The S&P 500’s latest surge gave way overnight, with fut...
A federal jury awarded $3 million to a woman in the first-ever social media addiction trial against Meta and Google, ...
Cathie Wood goes selling has people watching Ark Invest closely. This article breaks down three key trims, the reason...
Policymakers are weighing tax shifts that could touch luxury spending by the ultra-wealthy. Investors watch designer ...
A speculative bid by GameStop to purchase eBay sparks fresh debate about stock-based deals and the risk of overpaying...